Analysts’ Viewpoint on Anticoagulant Reversal Drugs Market Scenario
The global anticoagulant reversal drugs market is expected to grow at a rapid pace during the forecast period due to the rise in product approvals, awards, and innovations. Governments and private players are focusing on capitalizing on existing and new products to address unmet medical needs. Surge in number of hospital admissions due to bleeding disorders and high prevalence of atrial fibrillation among the geriatric population are likely to drive the global anticoagulation reversal drugs market in the next few years. Increase in pipeline products and favorable reimbursement scenario are the ongoing trends in the anticoagulant reversal drugs market. Key players operating in the market are striving to launch new products to meet the rising need for life-saving anticoagulant reversal drugs and expand their product portfolios.
Anticoagulants are medications used to prevent the blood layer from getting thick or coagulating. Anticoagulants help patients against life-threatening conditions such as heart attacks and pulmonary embolisms. Various types of reversal agents, such as Eliquis reversal agent and Xarelto reversal agent, are used to counter the effect of life threatening situations of uncontrolled bleeding. Vitamin K is the reversal agent for warfarin, while Praxbind is the reversal agent for Pradaxa, which has been approved for emergency situations.
Rise in usage of reversal agents for life-threatening conditions or uncontrolled bleeding is projected to drive the global anticoagulant reversal drugs market size in the near future. Increase in cases of bleeding is anticipated to lead to unmet clinical needs owing to the unavailability of specific reversal agents.
Some plasma-derived clotting factors are inactivated despite the presence of various coagulation factors at physiological concentrations in fresh frozen plasma (FFP) from healthy blood donors. Recent products include single clotting factor concentrate (e.g., factor VIII concentrate for hemophilia A and factor IX concentrate for hemophilia B) or prothrombin complex concentrate (PCC), which are aggregate plasma products of intermediate purity containing a mixture of vitamin K dependents. Prothrombin complex concentrate is prepared by ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools following removal of antithrombin and factor XI.
Some of the direct-acting oral anticoagulants (DOACs), such as dabigatran etexilate and direct anti-Xa anticoagulants, have been approved as a result of recent advancements in drug development (apixaban, betrixaban, edoxaban, and rivaroxaban). Currently, the DOACs, together with warfarin, represent the cornerstone of anticoagulant therapy in outpatient settings.
Intracranial hemorrhages (ICH) account for majority of bleeding cases in patients treated with DOAC; the annual prevalence rate ranges between 8% and 18%. Gastrointestinal (GI) hemorrhage is the most prevalent, accounting for more than 50% of major bleeding events. High prevalence of GI hemorrhages with DAOC can be ascribed to the lack of GI absorption, which leads to increased local drug level. Such high prevalence of bleeding events has resulted in the need for anticoagulant reversal agents to control bleeding due to the effect of the anticoagulant. This is expected to contribute to the growth of the global anticoagulant reversal drugs market during the forecast period.
Certain antidotes, which are designed to act specifically on some of the anticoagulants, have been granted the new technology add-on payment (NTAP) status by the U.S. Centers for Medicare and Medicaid Services (CMS). The status increases patient access to drugs by providing additional Medicare reimbursement in hospital settings. This is anticipated to augment the demand for these drugs. In turn, this is likely to propel the global market during the forecast period.
In terms of product, the global anticoagulant reversal drugs market has been classified into prothrombin complex concentrates (PCC), vitamin K, protamine, tranexamic acid, idarucizumab, AndeXXa, and others. The vitamin K segment accounted for major share of the global market in 2021. The segment is expected to grow at a rapid pace from 2022 to 2031. Increase in consumption of vitamin K for the reversal of warfarin and comparatively low cost of the drug are likely to propel the segment during the forecast period.
Based on distribution channel, the hospital pharmacies segment accounted for the largest global anticoagulant reversal drugs market share in 2021. The segment is expected to witness strong growth from 2022 to 2031 owing to the rise in usage of anticoagulant drugs during surgical procedures to control excessive bleeding and life-threatening hemorrhage disorders. Furthermore, these drugs are commonly available in hospital pharmacies, as they are used in emergency procedures.
North America dominated the global anticoagulant reversal drugs market in 2021. The market in the region is driven by the rise in new product development, approvals, and launch of anticoagulation reversal drugs in the U.S. and Canada.
The anticoagulant reversal drugs market in Europe is anticipated to grow at a moderate pace during the forecast period. Germany is a highly lucrative market for anticoagulant reversal drugs. The can be ascribed to high prevalence rate of atrial fibrillation, increase in geriatric population with age-related bleeding disorders, and surge in number of hospital admissions with factor Xa inhibitors in the country.
The market in Asia Pacific is projected to grow at a rapid pace during the forecast period. Increase in geriatric population in Japan and China, high prevalence & rise in incidence rates of arterial fibrillation, and new product commercialization are anticipated to propel the anticoagulant reversal drugs market in Asia Pacific during the forecast period.
The global anticoagulant reversal drugs market is consolidated, with the presence of a small number of large companies. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the key players. Prominent players in the global anticoagulant reversal drugs market are Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc.
Each of these players has been profiled in the anticoagulant reversal drugs market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 829.5 Mn |
|
Market Forecast Value in 2031 |
More than US$ 2.3 Bn |
|
Growth Rate (CAGR) |
11.3% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global anticoagulant reversal drugs market was valued at US$ 829.5 Mn in 2021.
The global anticoagulant reversal drugs market is projected to reach more than US$ 2.4 Bn by 2031.
The global anticoagulant reversal drugs market is anticipated to grow at a CAGR 11.3% from 2022 to 2031.
Rise in prevalence of atrial fibrillation among the geriatric population and NTAP status for specific drugs are driving the global anticoagulant reversal drugs market.
North America is expected to account for the largest share of the global anticoagulant reversal drugs market during the forecast period.
Prominent players in the global anticoagulant reversal drugs market are Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc. and Perosphere Pharmaceuticals, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anticoagulant Reversal Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Key Industry Developments (mergers & acquisitions, product launches, partnerships)
5.2. Pipeline Analysis
5.3. Reimbursement Scenario by Region/globally
5.4. Regulatory Scenario by Region/Globally
5.5. Covid-19 Pandemic Impact on the Industry
6. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Prothrombin Complex Concentrates
6.3.2. Vitamin K
6.3.3. Protamine
6.3.4. Tranexamic Acid
6.3.5. Idarucizumab
6.3.6. AndeXXa
6.3.7. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017-2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Others
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Anticoagulant Reversal Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2017-2031
9.2.1. Prothrombin Complex Concentrates
9.2.2. Vitamin K
9.2.3. Protamine
9.2.4. Tranexamic Acid
9.2.5. Idarucizumab
9.2.6. AndeXXa
9.2.7. Others
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Anticoagulant Reversal Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017-2031
10.2.1. Prothrombin Complex Concentrates
10.2.2. Vitamin K
10.2.3. Protamine
10.2.4. Tranexamic Acid
10.2.5. Idarucizumab
10.2.6. AndeXXa
10.2.7. Others
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Prothrombin Complex Concentrates
11.2.2. Vitamin K
11.2.3. Protamine
11.2.4. Tranexamic Acid
11.2.5. Idarucizumab
11.2.6. AndeXXa
11.2.7. Others
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Anticoagulant Reversal Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Prothrombin Complex Concentrates
12.2.2. Vitamin K
12.2.3. Protamine
12.2.4. Tranexamic Acid
12.2.5. Idarucizumab
12.2.6. AndeXXa
12.2.7. Others
12.3. Market Value Forecast, by Distribution Channel, 2017-2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Prothrombin Complex Concentrates
13.2.2. Vitamin K
13.2.3. Protamine
13.2.4. Tranexamic Acid
13.2.5. Idarucizumab
13.2.6. AndeXXa
13.2.7. Others
13.3. Market Value Forecast, by Distribution Channel, 2017-2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2021)
14.3. Company Profiles
14.3.1. Amneal Pharmaceuticals, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Bausch Health Companies, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Boehringer Ingelheim GmbH
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. CSL Limited
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Fresenius Kabi AG
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Perosphere Pharmaceuticals, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Pfizer, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Portola Pharmaceuticals, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Octapharma AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
List of Tables
Table 01: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
Table 02: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 03: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Region, 2017-2031
Table 04: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017-2031
Table 05: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
Table 06: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 07: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 08: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
Table 09: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 10: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 11: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
Table 12: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
Table 15: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2017-2031
Table 18: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Distribution, by Geography, 2021-2031
Figure 02: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Forecast, 2022-2031
Figure 03: Global Anticoagulant Reversal Drugs Market Value Share, by Product, 2021
Figure 04: Global Anticoagulant Reversal Drugs Market Value Share, by Distribution Channel, 2021
Figure 05: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2021
Figure 06: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
Figure 07: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Prothrombin Complex Concentrates (PCC) 2017-2031
Figure 08: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Vitamin K, 2017-2031
Figure 09: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Protamine, 2017-2031
Figure 10: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Tranexamic Acid, 2017-2031
Figure 11: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017-2031
Figure 12: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Idarucizumab, 2017-2031
Figure 13: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by AndeXXa, 2017-2031
Figure 14: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
Figure 15: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
Figure 16: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 17: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031
Figure 18: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031
Figure 19: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%),
Figure 20: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2021-2031
Figure 21: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Region, 2022-2031
Figure 22: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 23: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country, 2021-2031
Figure 24: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country, 2022-20316
Figure 25: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
Figure 26: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
Figure 27: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
Figure 28: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 32: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 33: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2021-2031
Figure 34: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-20316
Figure 35: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
Figure 36: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
Figure 37: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
Figure 38: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 39: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 40: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2021-2031
Figure 41: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 42: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
Figure 43: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
Figure 44: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
Figure 45: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 46: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 47: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2021-2031
Figure 48: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 49: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
Figure 50: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
Figure 51: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
Figure 52: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 53: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 54: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2021-2031
Figure 55: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 56: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2021-2031
Figure 57: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2031
Figure 58: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2021-2031
Figure 59: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 60: Global Anticoagulant Reversal Drugs Market Share Analysis, by Company (2021)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Anticoagulant Reversal Drugs Market
